Hepatitis B inactive carriers: Clinical course and outcomes

Journal of Digestive Diseases

Volumn 14, Issue 6, 2013, Pages 311-317

  Tong, Myron J ^a,b,c   Trieu, Judy ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alanine aminotransferase; Hepatitis B virus; Hepatitis B virus DNA; Hepatocellular carcinoma; Inactive carrier

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; CHILD; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84876997223     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12051     Document Type: Article

References (29)

1. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005; 118: 1413.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
3. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366.
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
5. Chen CF, Lee WC, Yang HI etal; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 1240-1248, 1248.e1-2.
6. Liu CJ, Chen BF, Chen PJ etal. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193: 1258-1265.
7. Tong MJ, Hsu L, Hsien C etal. A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int 2010; 4: 516-522.
8. Hui CK, Leung N, Yuen ST etal; Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395-401.
9. Tong MJ, Pan CQ, Hann HW etal. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011; 56: 3143-3162.
10. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J 2005; 2: 82.
11. de Franchis R, Meucci G, Vecchi M etal. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-194.
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
13. Keeffe EB, Dieterich DT, Han SH etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341; quiz 1286.
14. Tong MJ, Hsien C, Song JJ etal. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 2009; 54: 1337-1346.
15. Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 6620-6626.
16. Chen JD, Yang HI, Iloeje UH etal; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-1754.
17. Liu XD, Wu JL, Liang J, Zhang T, Sheng QS. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol 2012; 18: 2784-2792.
18. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012; 7: e34198.
19. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
20. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-145.
21. Hoofnagle JH, Dusheiko GM, Schafer DF etal. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-449.
22. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-871.
23. Huo TI, Wu JC, Lee PC etal. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231-236.
24. Tong MJ, Nguyen MO, Tong LT, Blatt LM. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2009; 7: 889-893.
25. Hsu YS, Chien RN, Yeh CT etal. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527.
26. Popper H, Shafritz DA, Hoofnagle JH. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology 1987; 7: 764-772.
27. Lin CL, Liao LY, Liu CJ etal. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007; 45: 1193-1198.
28. Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007; 27: 1356-1363.
29. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767.